Study Comparing the Tolerability of Seroquel IR with Seroquel XR in Patients with Bipolar Depression

Study identifier:D1443C00040

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase IV, Multi-center, Double-blind, Double-dummy, Randomized, Parallel-group Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (Seroquel IR) with Quetiapine Fumarate Extended Release (Seroquel XR) During Initial Dose Escalation in Patients with Bipolar Depression

Medical condition

bipolar depression

Phase

Phase 4

Healthy volunteers

No

Study drug

Quetiapine Immediate Release, Quetiapine Extended Release

Sex

All

Actual Enrollment

139

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 01 Jun 2009
Primary Completion Date: 01 Aug 2009
Study Completion Date: 01 Aug 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Other

Verification:

Verified 01 May 2011 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria